Epigenetic therapy and cisplatin chemoradiation in FIGO Stage IIIB cervical cancer

European Journal of Gynaecological Oncology

Volumn 31, Issue 4, 2010, Pages 386-391

  Candelaria, M ^b   Cetina, L ^b   Perez Cardenas E ^a   De La Cruz Hernandez E ^a   Gonzalez Fierro A ^a   Trejo Becerril, C ^a   Taja Chayeb, L ^a   Chanona, J ^b   Arias, D ^b   Duenas Gonzalez A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Chemoradiation; Epigenetic therapy; FIGO stage IIIB cervical cancer; Hydralazine; Valproate

Indexed keywords

CISPLATIN; DEXAMETHASONE; HYDRALAZINE; ONDANSETRON; SULFADIMIDINE; VALPROATE MAGNESIUM; ANTINEOPLASTIC AGENT; VALPROIC ACID;

ABDOMINAL PAIN; ACETYLATOR PHENOTYPE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLADDER DISCOMFORT; BLEEDING; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; EDEMA; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GYNECOLOGY; HEADACHE; HOT FLUSH; HUMAN; HYPOALBUMINEMIA; HYPOREXIA; LEUKOPENIA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OBSTETRICS; OTOTOXICITY; PELVIS PAIN SYNDROME; PROCTITIS; RADIATION DOSE; RADIOEPITHE; SINGLE DRUG DOSE; SLOW DRUG RELEASE; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UTERINE CERVIX CANCER; VOMITING; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; EPIGENESIS, GENETIC; FEMALE; HUMANS; HYDRALAZINE; MIDDLE AGED; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

EID: 77956123071     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Zhu W.G., Otterson G.A.: "The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells". Curr. Med. Chem. Anti-Cancer Agents, 2003, 3, 187.
2. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B.: "Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer". Nature Genet., 1999, 21, 103.
3. Zhu W.G., Lakshmanan R.R., Beal M.D., Otterson G.A.: "DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors". Cancer Res., 2001, 61, 1327.
4. Hellebrekers D.M., Griffioen A.W., van Engeland M.: "Dual targeting of epigenetic therapy in cancer". Biochim. Biophys Acta, 2007, 1775, 76.
5. Ciernik I.F., Forrer C., Hofstetter B., Bosman F., Pruschy M.: "Demethylation with 5-azacytidine increases radiation sensitivity of colorectal carcinoma cell lines". Radiat. Oncol., 2004, 73, S1.
6. Dote H., Cerna D., Burgan W.E., Carter D.J., Cerra M.A., Hollingshead M.G. et al.: "Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine". Clin. Cancer Res., 2005, 11, 4571.
7. Zhang Y., Jung M., Dritschilo A., Jung M.: "Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors". Radiat. Res., 2004, 161, 667.
8. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L. et al.: "Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity". Clin. Cancer Res., 2005, 11, 4912.
9. Karagiannis T.C., Smith A.J., El' Osta A.: "Radio- and chemosensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A". Hell. J. Nucl. Med., 2004, 7, 184.
10. Camphausen K., Cerna D., Scott T., Sproull M., Burgan W.E., Cerra M.A. et al.: "Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid". Int. J. Cancer, 2005, 114, 380.
11. Chung Y.L., Wang A.J., Yao L.F.: "Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy". Mol. Cancer Ther., 2004, 3, 317.
12. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Mariscal I., Chavez A. et al.: "Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy". Clin. Cancer Res., 2003, 9, 1596.
13. Song Y., Zhang C.: "Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and reexpression". Cancer Chemother. Pharmacol., 2009, 63, 605.
14. Law A.Y., Lai K.P., Ip C.K., Wong A.S., Wagner G.F., Wong C.K.: "Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells". Exp. Cell. Res., 2008, 314, 1823.
15. Wang X., Chao L., Jin G., Ma G., Zang Y., Sun J.: "Association between CpG island methylation of the WWOX gene and its expression in breast cancers". Tumor Biol., 2009, 30, 8.
16. Chavez-Blanco A., Perez-Plasencia C., Perez-Cardenas E., Carrasco-Legleu C., Rangel-Lopez E., Segura-Pacheco B. et al.: "Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines". Cancer Cell. Int., 2006, 6, 2.
17. Li H., Chen S., Shu Y., Chen Y., Su Y., Wang X., Zou S.: "Synergy of DNA methylation and histone deacetylase inhibitors in the reexpression of RASSF1A and P16 genes silenced in QBC cells". Chinese-German J. Clin. Oncol., 2008, 7, 627.
18. Li H., Chen S., Shu Y., Chen Y., Su Y., Wang X. et al.: "Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness and the invasiveness of QBC939 cells". Frontiers Med. China, 2009, 3, 153.
19. Candelaria M., Gallardo-Rincón D., Arce C., Cetina L., Aguilar-Ponce J.L., Arrieta O., González et al.: "A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors". Ann. Oncol., 2007, 18, 1529.
20. Arce C., Pérez-Plasencia C., González-Fierro A., de la Cruz-Hernández E., Revilla-Vázquez A., Chávez-Blanco A. et al.: "A proof-ofprinciple study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer". PLoS ONE, 2006, 1, e98.
21. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A.: "Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors". Cancer Treat. Rev., 2008, 34, 206.
22. Zambrano P., Segura-Pacheco B., Perez-Cardenas E., Cetina L., Revilla-Vazquez A., Taja-Chayeb L. et al.: "A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes". BMC Cancer, 2005, 5, 44.
23. Phiel C.J., Huan E.Y., Guenter M.G., Lazar M.A., Klein P.S.: "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen". J. Biol. Chem., 2001, 276, 36734.
24. Kramer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A. et al.: "The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2". EMBO J., 2003, 22, 3411.
25. Chávez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M. et al.: "Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study". Mol. Cancer, 2005, 4, 22.
26. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K. et al.: "Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia". Cancer, 2005, 104, 2717.
27. García-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S. et al.: "Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia". Blood, 2006, 108, 3271.
28. Mora-Garcia M. de L., Duenas-González A., Hernández-Montes J., De la Cruz-Hernández E., Pérez-Cárdenas E., Weiss-Steider B. et al.: "Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid". J. Transl. Med., 2006, 4, 55.
29. de la Cruz-Hernandez E., Pérez-Cárdenas E., Contreras-Paredes A., Cantú D., Mohar A., Lizano M. et al.: "The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study". Virol. J., 2007, 4, 18.
30. Duenas-Gonzalez A., Lizano M., Candelaria M., Cetina L., Arce C., Cervera E.: "Epigenetics of cervical cancer. An overview and therapeutic perspectives". Mol. Cancer, 2005, 4, 38.
31. Dueñas-González A., Cetina L., Mariscal I., de la Garza J.: "Modern management of locally advanced cervical carcinoma". Cancer Treat. Rev., 2003, 29, 389.
32. Aparicio A., Weber J.S.: "Review of the clinical experience with 5-azacytidine and 5-aza-2′- deoxycytidine in solid tumors". Curr. Opin. Invest. Drugs, 2002, 3, 627.
33. Schwartsmann G., Schunemann H., Gorini C.N., Filho A.F., Garbino C., Sabini G. et al.: "A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer". Invest. New Drugs, 2000, 18, 83.
34. Pohlmann P., DiLeone L.P., Cancella A.I., Caldas A.P., Dal Lago L., Campos O. Jr. et al.: "Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix". Am. J. Clin. Oncol., 2002, 25, 496.
35. Duvic M., Vu J.: "Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma". Expert Opin. Invest. Drugs, 2007, 16, 1111.
36. Cetina L., Rivera L., Hinojosa J., Poitevin A., Uribe J., López-Graniel C. et al.: "The routine management of locally advanced cervical cancer with concurrent radiation and cisplatin, five year results". BMC Women's Health, 2006, 6, 3.
37. Safar A.M., Macleod S., Klimber V., Henri-Tillman R., Fan C., Hutchins L. et al.: "Hydralazine-demethylating systemic therapy for breast cancer". J. Clin. Oncol., 2006, 24 (suppl. 18S), 13131.
38. Voso M.T., Santini V., Finelli C., Musto P., Pogliani E., Angelucci E. et al.: "Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes". Clin. Cancer Res., 2009, 15, 5002.
39. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.
40. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C. Jr. et al.: "A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study". J. Clin. Oncol., 1999, 17, 1339.
41. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A. et al.: "Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer". N. Engl. J. Med., 1999, 340, 1144.
42. Rose P.G., Ali S., Watkins E., Thigpen J.T., Deppe G., Clarke-Pearson D.L. et al.: "Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study". J. Clin. Oncol., 2007, 25, 2804.
43. Saibishkumar E.P., Patel F.D., Sharma S.C.: "Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients". Int. J. Gynecol. Cancer, 2005, 15, 890.
44. Yalman D., Aras A.B., Ozkök S., Duransoy A., Celik O.K., Ozsaran Z. et al.: "Prognostic factors in definitive radiotherapy of uterine cervical cancer". Eur. J. Gynaecol. Oncol., 2003, 24, 309.
45. Han I., Orton C., Shamsa F., Hart K., Strowbridge A., Deppe G. et al.: "Combined low-dose-rate brachytherapy and external beam radiation for cervical cancer: experience over ten years". Radiat. Oncol. Invest., 1999, 7, 289.
46. Eifel P.J., Winter K., Morris M., Levenback C., Grigsby P.W., Cooper J. et al.: "Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01". J. Clin. Oncol., 2004, 22, 872.
47. Saibishkumar E.P., Patel F.D., Sharma S.C., Karunanidhi G., Ghoshal S., Kumar V. et al.: "Prognostic value of response to external radiation in Stage IIB cancer cervix in predicting clinical outcomes: a retrospective analysis of 556 patients from India". Radiother. Oncol., 2006, 79, 142.
48. Saibishkumar E.P., Patel F.D., Sharma S.C., Karunanidhi G., Sankar A.S., Mallick I.: "Results of external-beam radiotherapy alone in invasive cancer of the uterine cervix: a retrospective analysis". Clin. Oncol. (R. Coll. Radiol.), 2006, 18, 46.